Delivery of Small Interfering RNA. A Review and an Example of Application to a Junction Oncogene

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Tumori

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/030089160809400218PMID 18564614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delivery Vehicles for Small Interfering RNA In Vivo

  2008cited by this paper
• Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA.

  2008cited by this paper
• Lipid-based Nanoparticles for Nucleic Acid Delivery

  2007cited by this paper
• Strategies for silencing human disease using RNA interference

  2007cited by this paper
• Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.

  2007cited by this paper
• Encapsulation of Nucleic Acids and Opportunities for Cancer Treatment

  2007cited by this paper
• siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma

  2007cited by this paper
• Nonviral delivery of synthetic siRNAs in vivo.

  2007cited by this paper
• [Downregulation of HER2 by adenovirus-mediated RNA interference and its inhibitory effect on growth of SKBR3 breast cancer cell].

  2007cited by this paper
• Down-regulation of EDAG expression by retrovirus-mediated small interfering RNA inhibits the growth and IL-8 production of leukemia cells.

  2007cited by this paper
• Guidelines for the selection of effective short-interfering RNA sequences for functional genomics.

  2007cited by this paper
• Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).

  2007cited by this paper
• Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA

  2007cited by this paper
• Targeted delivery systems of small interfering RNA by systemic administration.

  2007cited by this paper
• Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

  2006cited by this paper
• INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES

  2006cited by this paper
• Efficacy of siRNA Nanocapsules Targeted Against the EWS–Fli1 Oncogene in Ewing Sarcoma

  2006cited by this paper
• Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo

  2006cited by this paper
• Nanocarriers: promising vehicle for bioactive drugs.

  2006cited by this paper
• Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.

  2006cited by this paper
• RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

  2006cited by this paper
• RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

  2006cited by this paper
• Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect

  2006cited by this paper
• Off-target effects by siRNA can induce toxic phenotype.

  2006cited by this paper
• Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing.

  2006cited by this paper
• RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.

  2006cited by this paper
• Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis.

  2006cited by this paper
• Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

  2005cited by this paper
• Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency.

  2005cited by this paper
• DNA-based therapeutics and DNA delivery systems: A comprehensive review

  2005cited by this paper
• Polypropylenimine dendrimer-induced gene expression changes: The effect of complexation with DNA, dendrimer generation and cell type

  2005cited by this paper
• RNAi-induced gene silencing by local electroporation in targeting brain region.

  2005cited by this paper
• Molecular genetics of multiple endocrine neoplasia types 1 and 2

  2005cited by this paper
• Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector.

  2005cited by this paper
• Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain

  2005cited by this paper
• Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents.

  2005cited by this paper
• Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells

  2004cited by this paper
• RNA interference using boranophosphate siRNAs: structure-activity relationships.

  2004cited by this paper
• A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.

  2004cited by this paper
• Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

  2004cited by this paper
• Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.

  2004cited by this paper
• Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer

  2004cited by this paper
• Progress in the Development of Nucleic Acids Therapeutics for Cancer

  2004cited by this paper
• Delivery of bioactive molecules into the cell: the Trojan horse approach.

  2004cited by this paper
• Biodistribution of phosphodiester and phosphorothioate siRNA.

  2004cited by this paper
• Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

  2003cited by this paper
• LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1

  2003cited by this paper
• Optimisation of dendrimer‐mediated gene transfer by anionic oligomers

  2003cited by this paper
• Activation of the interferon system by short-interfering RNAs

  2003cited by this paper
• Use of adeno-associated viral vector for delivery of small interfering RNA

  2003cited by this paper
• Gene expression: RNA interference in adult mice

  2002cited by this paper
• Gene Therapy Progress and Prospects: Nonviral vectors

  2002cited by this paper
• Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate

  2001cited by this paper
• Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

  2001cited by this paper
• Molecular Modeling of the Extracellular Domain of the RET Receptor Tyrosine Kinase Reveals Multiple Cadherin-like Domains and a Calcium-binding Site*

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Nanoparticulate systems for the delivery of antisense oligonucleotides.

  2001cited by this paper
• RET Oncogene Activation in Papillary Thyroid Carcinoma

  2001cited by this paper
• RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

  2000cited by this paper
• Development of biomaterials for gene therapy.

  2000cited by this paper
• Molecular basis of Hurthle cell papillary thyroid carcinoma

  2000cited by this paper
• Molecular basis off hurthle cell papillary thyroid carcinoma.

  2000cited by this paper
• EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice.

  2000cited by this paper
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999cited by this paper
• Fundamentals of electroporative delivery of drugs and genes.

  1999cited by this paper
• High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.

  1999cited by this paper
• Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides

  1999cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides.

  1998cited by this paper
• High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation

  1997cited by this paper
• A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.

  1997cited by this paper
• Progress in antisense therapeutics

  1996cited by this paper
• Progress in antisense therapeutics.

  1996cited by this paper
• The physical map of the human RET proto-oncogene.

  1995cited by this paper
• Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

  1995cited by this paper
• Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression.

  1994cited by this paper
• Characterization of the ret proto-oncogene products expressed in mouse L cells.

  1993cited by this paper
• In vitro irradiation is able to cause RET oncogene rearrangement.

  1993cited by this paper
• Electroporation and electrophoretic DNA transfer into cells. The effect of DNA interaction with electropores.

  1992cited by this paper
• Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans.

  1990cited by this paper
• Transferrin-polycation conjugates as carriers for DNA uptake into cells.

  1990cited by this paper
• Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

  1987cited by this paper
• Activation of a novel human transforming gene, ret, by DNA rearrangement.

  1985cited by this paper

• Surface engineered nanodiamonds: mechanistic intervention in biomedical applications for diagnosis and treatment of cancer

  2024cites this paper
• Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier

  2020cites this paper
• Production, surface modification and biomedical applications of nanodiamonds: A sparkling tool for theranostics.

  2019cites this paper
• Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model.

  2017cites this paper
• The AGMA1 polyamidoamine mediates the efficient delivery of siRNA

  2017cites this paper
• Analysis of the significance of miRNAs of the miRNA-200 family in the malignant phenotype of glioblastoma

  2017cites this paper
• Biomedical Applications of Nanodiamonds: An Overview.

  2015cites this paper
• Advances in Therapeutic Approaches Using RNA Interference as a Gene Silencing Tool

  2013cites this paper
• Identification of critical points in colloidal delivery systems for intravenous administration and intracellular delivery of nucleic acids as therapeutic agents

  2012cites this paper
• Elucidation of gene function using RNA interference in a cancer cell culture model.

  2011cites this paper
• Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells.

  2011cites this paper
• Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research.

  2010cites this paper
• pH-responsive polymeric micelle carriers for siRNA drugs.

  2010cites this paper
• Efficient Gene Silencing in Lungs and Liver Using Imidazole-Modified Chitosan As a Nanocarrier for Small Interfering RNA

  2010cites this paper
• Development of a novel endosomolytic diblock copolymer for siRNA delivery.

  2009cites this paper
• Paradigm changes in medical science.

  2008cites this paper
• Paradigm Changes in Medical Science

  2008cites this paper
• Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

  2008cites this paper